Catabasis Pharmaceuticals (NASDAQ:CATB)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a note issued to investors on Wednesday. They presently have a $4.00 price target on the biotechnology company’s stock, down from their previous price target of $5.00. Wedbush’s price objective would indicate a potential upside of 187.77% from the stock’s previous close.
Other analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Citigroup raised shares of Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Monday, November 20th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $4.82.
Catabasis Pharmaceuticals (NASDAQ CATB) traded down $0.17 during midday trading on Wednesday, hitting $1.39. 3,141,986 shares of the stock traded hands, compared to its average volume of 1,110,000. The firm has a market capitalization of $32.09 and a price-to-earnings ratio of -0.92. Catabasis Pharmaceuticals has a 12 month low of $1.09 and a 12 month high of $3.78.
WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/catabasis-pharmaceuticals-catb-outperform-rating-reiterated-at-wedbush.html.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.